# Targeted Radiation Therapy for Ovarian Cancer: Intraperitoneal Treatment With 211-astatine-MX35 F(ab')2

> **NCT04461457** · EARLY_PHASE1 · COMPLETED · sponsor: **Vastra Gotaland Region** · enrollment: 12 (actual)

## Conditions studied

- Ovarian Cancer

## Interventions

- **COMBINATION_PRODUCT:** 211-astatine MX35 F(ab')2

## Key facts

- **NCT ID:** NCT04461457
- **Lead sponsor:** Vastra Gotaland Region
- **Sponsor class:** OTHER_GOV
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-02-05
- **Primary completion:** 2011-03-19
- **Final completion:** 2012-01-19
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2020-07-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04461457

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04461457, "Targeted Radiation Therapy for Ovarian Cancer: Intraperitoneal Treatment With 211-astatine-MX35 F(ab')2". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT04461457. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*